You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 8, 2025

Drug Price Trends for ABACAVIR-LAMIVUDINE


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for ABACAVIR-LAMIVUDINE

Average Pharmacy Cost for ABACAVIR-LAMIVUDINE

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug Name NDC Price/Unit ($) Unit Date
ABACAVIR-LAMIVUDINE 600-300 MG 68180-0288-06 1.64061 EACH 2025-01-22
ABACAVIR-LAMIVUDINE 600-300 MG 69097-0362-02 1.64061 EACH 2025-01-22
ABACAVIR-LAMIVUDINE 600-300 MG 42385-0962-30 1.64061 EACH 2025-01-22
ABACAVIR-LAMIVUDINE 600-300 MG 65862-0335-30 1.64061 EACH 2025-01-22
ABACAVIR-LAMIVUDINE 600-300 MG 65862-0335-30 1.56657 EACH 2024-12-18
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Market Analysis and Price Projections for Abacavir-Lamivudine

Introduction to Abacavir-Lamivudine

Abacavir-lamivudine, commonly known by the brand name Epzicom, is an antiviral combination drug used primarily for the treatment of HIV infection, as well as for nonoccupational and occupational exposure to HIV. This medication combines two active ingredients: abacavir and lamivudine, both of which are nucleoside reverse transcriptase inhibitors (NRTIs)[2].

Market Scope and Geographic Distribution

The market for abacavir-lamivudine is global, with significant presence in North America, Europe, Japan, BRIC countries (Brazil, Russia, India, China), and Australia. Reports from Research and Markets provide detailed insights into the sales trends, pricing, and forecasts for this drug in these regions[1][3].

Key Markets

  • United States: One of the largest markets for abacavir-lamivudine, with a substantial patient base and high demand for antiretroviral therapies.
  • Europe: Countries such as Germany, France, Italy, Spain, and the UK also have a significant market share.
  • BRIC Countries: Emerging markets in Brazil, Russia, India, and China are growing due to increasing healthcare expenditure and access to antiretroviral therapies.
  • Japan and Australia: These countries also contribute to the global sales of abacavir-lamivudine.

Sales Analysis

Historical sales data for abacavir-lamivudine show a steady growth trend, driven by the increasing prevalence of HIV and the need for effective antiretroviral therapies. The sales analysis includes:

  • Global Sales: The total sales revenue of abacavir-lamivudine worldwide has been increasing, reflecting the drug's efficacy and market demand.
  • Country-Specific Sales: Sales trends vary by country, with some regions showing higher growth rates due to better healthcare infrastructure and higher patient awareness[1][3].

Price Analysis

The pricing of abacavir-lamivudine varies significantly depending on the country, pharmacy, and whether the drug is purchased as a brand name or generic.

Brand Name Pricing

  • The brand name version, Epzicom, is priced around $1,370 for a supply of 30 tablets in the United States, making it a costly option for many patients[5].

Generic Pricing

  • Generic versions of abacavir-lamivudine are significantly cheaper, priced around $120.97 for 30 tablets, making them a more affordable option for patients[2].

Price Trends and Benchmarks

  • The unit price of abacavir-lamivudine has been analyzed across different countries, providing benchmarks for pricing strategies and competitive intelligence. These analyses help in understanding the price dynamics and in devising pricing strategies[1][3].

Sales Forecast

Sales forecasts for abacavir-lamivudine indicate continued growth, driven by several factors:

  • Increasing Prevalence of HIV: The global HIV prevalence is expected to remain a significant health issue, driving the demand for antiretroviral therapies.
  • Generic Competition: The availability of generic versions is expected to increase market penetration, especially in regions with lower healthcare budgets.
  • Market Expansion: Emerging markets in BRIC countries and other regions are expected to contribute to the growth in sales[1][3].

Global Sales Forecast

  • The global sales forecast for abacavir-lamivudine projects steady growth until 2021 and beyond, reflecting the ongoing need for effective HIV treatments.

Country-Specific Sales Forecast

  • Sales forecasts by country indicate varying growth rates, with some countries showing higher growth due to better healthcare access and increasing patient awareness.

Competitive Intelligence and Market Dynamics

The market for abacavir-lamivudine is competitive, with several companies marketing the drug under different brand names. Key players include:

  • Original Manufacturers: Companies that originally developed and marketed the drug.
  • Generic Manufacturers: Companies that produce and market generic versions of abacavir-lamivudine, offering cost-effective alternatives[1][3].

Brand Planning and Product Positioning

  • Companies use sales and price data to position their products effectively in the market, focusing on brand planning, product strategy, and competitive intelligence.

Generic Trends

  • The availability of generic versions of abacavir-lamivudine has significantly impacted the market, offering patients more affordable treatment options and influencing the sales trends of the brand name versions[4].

Cost Considerations and Economic Impact

The cost of antiretroviral therapy, including abacavir-lamivudine, is a critical factor in healthcare planning and budgeting.

Cost-Effectiveness

  • Studies have shown that transitioning to generic versions of antiretroviral drugs can result in significant cost savings. For example, a study indicated that switching from branded to generic versions of certain ARV regimens could save nearly $1 billion[4].

Patient Assistance Programs

  • Various patient assistance programs, including coupons, copay cards, and rebates, are available to help patients afford the medication. These programs are crucial in making the drug more accessible to those in need[2][5].

Regulatory and Patent Considerations

The patent status of abacavir-lamivudine affects its market dynamics. With the patent protection expiring for some components, generic versions have become more prevalent, impacting the sales of brand name versions.

Patent Expiration

  • The expiration of patents for abacavir and lamivudine has led to the entry of generic manufacturers, increasing competition and reducing prices.

Regulatory Approvals

  • Regulatory approvals for generic versions in various countries have expanded the market, making the drug more accessible globally[4].

Key Takeaways

  • Global Demand: The demand for abacavir-lamivudine is driven by the global prevalence of HIV and the need for effective antiretroviral therapies.
  • Pricing Dynamics: The pricing of abacavir-lamivudine varies significantly between brand name and generic versions, with generics offering a more affordable option.
  • Sales Forecast: Sales forecasts indicate continued growth, driven by increasing demand and market expansion.
  • Competitive Intelligence: The market is competitive, with both original manufacturers and generic manufacturers playing significant roles.
  • Cost-Effectiveness: Transitioning to generic versions can result in significant cost savings, making antiretroviral therapy more accessible.

FAQs

What is abacavir-lamivudine used for?

Abacavir-lamivudine is used for the treatment of HIV infection, as well as for nonoccupational and occupational exposure to HIV.

How much does abacavir-lamivudine cost?

The cost of abacavir-lamivudine varies. The brand name version, Epzicom, costs around $1,370 for 30 tablets, while the generic version costs around $120.97 for 30 tablets.

Are there any patient assistance programs available for abacavir-lamivudine?

Yes, various patient assistance programs, including coupons, copay cards, and rebates, are available to help patients afford the medication.

What is the impact of generic versions on the market?

The availability of generic versions of abacavir-lamivudine has significantly reduced prices and increased market penetration, especially in regions with lower healthcare budgets.

How does the patent status affect the market for abacavir-lamivudine?

The expiration of patents for abacavir and lamivudine has led to the entry of generic manufacturers, increasing competition and reducing prices.

Sources

  1. Research and Markets, "Abacavir / Lamivudine Sales, Price Analysis, & Sales Forecast - 2017"
  2. Drugs.com, "Abacavir/lamivudine Prices, Coupons, Copay Cards & Patient Assistance"
  3. Research and Markets, "Global Abacavir / Lamivudine / Zidovudine Sales, Price Analysis, & Sales Forecast - 2017"
  4. Clinical Info HIV.gov, "Cost Considerations and Antiretroviral Therapy"
  5. Drugs.com, "Epzicom Prices, Coupons, Copay Cards & Patient Assistance"

More… ↓

⤷  Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.